Extended-field radiation therapy with whole pelvis radiotherapy and cisplatin chemosensitization in the treatment of IB2-IIIB cervical carcinoma: a retrospective review

Published:April 27, 2009DOI:


      This retrospective study evaluated the toxicity of extended-field radiation therapy (EFRT), whole pelvis radiotherapy, and concurrent chemotherapy in patients treated with IB2-IIIB cervical carcinoma.

      Study Design

      Patients treated with EFRT, whole pelvis radiotherapy, and concurrent chemotherapy were analyzed for toxicity. Median prescribed dose to the whole pelvis was 45 Gy (45-50 Gy). Median prescribed dose to the paraaortic lymph nodes was 45 Gy (36-50). Thirty-five patients received cisplatin chemosensitization at a median dose of 40 mg/m2 (40-51), with a median of 5 cycles (2-6).


      Thirty-six patients were treated, 3 with positive paraaortic lymph nodes. The median follow-up interval was 32 months. Twenty-four patients (66.7%) had no evidence of disease at last follow-up. Thirteen patients (36.1%) had recurrence. Fifteen patients (41.7%) experienced acute grade 3 toxicity.


      Increased toxicity in patients warrants careful patient selection.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Jemal J.
        • Siegel R.
        • Ward E.
        • et al.
        Cancer statistics, 2008.
        CA Cancer J Clin. 2008; 58: 71-96
        • Morris M.
        • Eifel P.J.
        • Lu J.
        • et al.
        Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
        N Engl J Med. 1999; 340: 1137-1143
        • Rose P.G.
        • Bundy B.N.
        • Watkins E.B.
        • et al.
        Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
        N Engl J Med. 1999; 340: 1144-1153
        • Keys H.M.
        • Bundy B.N.
        • Stehman F.B.
        • et al.
        Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma.
        N Engl J Med. 1999; 340: 1154-1161
        • Whitney C.W.
        • Sause W.
        • Bundy B.N.
        • et al.
        Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a gynecologic oncology group and southwest oncology group study.
        J Clin Oncol. 1999; 17: 1339-1348
        • Green J.A.
        • Kirwan J.M.
        • Tierney J.F.
        • et al.
        Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis.
        Lancet. 2001; 358: 781-786
        • Lukka H.
        • Hirte H.
        • Fyles A.
        • et al.
        Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer—a meta-analysis.
        Clin Oncol (R Coll Radiol). 2002; 14: 203-212
        • Eifel P.J.
        • Winter K.
        • Morris M.
        • et al.
        Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.
        J Clin Oncol. 2004; 22: 872-880
        • Mitsuhashi A.
        • Uno T.
        • Tanaka N.
        • et al.
        Phase I study of daily cisplatin and concurrent radiotherapy in patients with cervical carcinoma.
        Gynecol Oncol. 2005; 96: 194-197
        • Berman M.L.
        • Keys H.
        • Creasman W.
        • DiSaia P.
        • Bundy B.
        • Blessing J.
        Survival and patterns of recurrence in cervical cancer metastatic to periaortic lymph nodes (a gynecologic oncology group study).
        Gynecol Oncol. 1984; 19: 8-16
        • Rotman M.
        • Pajak T.F.
        • Choi K.
        • et al.
        Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas.
        JAMA. 1995; 274: 387-393
        • Malfetano J.H.
        • Keys H.
        • Cunningham M.J.
        • Gibbons S.
        • Ambros R.
        Extended field radiation and cisplatin for stage IIB and IIIB cervical carcinoma.
        Gynecol Oncol. 1997; 67: 203-207
        • Chung Y.L.
        • Jian J.J.
        • Cheng S.H.
        • et al.
        Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study.
        Gynecol Oncol. 2005; 97: 126-135
        • Sood B.M.
        • Timmins P.F.
        • Gorla G.R.
        • et al.
        Concomitant cisplatin and extended field radiation therapy in patients with cervical and endometrial cancer.
        Int J Gynecol Cancer. 2002; 12: 459-464
        • Gerszten K.
        • Colonello K.
        • Heron D.E.
        • et al.
        Feasibility of concurrent cisplatin and extended field radiation therapy (EFRT) using intensity-modulated radiotherapy (IMRT) for carcinoma of the cervix.
        Gynecol Oncol. 2006; 102: 182-188
        • Uno T.
        • Mitsuhashi A.
        • Isobe K.
        • et al.
        Concurrent daily cisplatin and extended-field radiation therapy for carcinoma of the cervix.
        Int J Gynecol Cancer. 2008; 18: 80-84
        • Grigsby P.W.
        • Heydon K.
        • Mutch D.G.
        • Kim R.Y.
        • Eifel P.
        Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
        Int J Radiat Oncol Biol Phys. 2001; 51: 982-987
        • Sood B.M.
        • Gorla G.R.
        • Garg M.
        • et al.
        Extended-field radiotherapy and high-dose-rate brachytherapy in carcinoma of the uterine cervix: clinical experience with and without concomitant chemotherapy.
        Cancer. 2003; 97: 1781-1788
        • Varia M.A.
        • Bundy B.N.
        • Deppe G.
        • et al.
        Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study.
        Int J Radiat Oncol Biol Phys. 1998; 42: 1015-1023
        • Gan G.N.
        • Beriwal S.
        • Krivak T.C.
        • et al.
        Concurrent chemotherapy and extended-field, intensity-modulated radiotherapy for cervical cancer: updated results and extended follow-up.
        Gynecol Oncol. 2009; 112: S16-S17
        • Gao W.
        • Thawani N.
        • Mutyala S.
        • et al.
        Comparison of early outcomes of concomitant chemoradiotherapy using intensity-modulated radiation therapy versus conventional radiotherapy for treatment of locally advanced cervical cancer.
        Gynecol Oncol. 2009; 112: S42-S43